DrugPatentWatch Database Preview
Sarepta Theraps Inc Company Profile
What is the competitive landscape for SAREPTA THERAPS INC, and when can generic versions of SAREPTA THERAPS INC drugs launch?
SAREPTA THERAPS INC has one approved drug.
There are five US patents protecting SAREPTA THERAPS INC drugs.
There are one hundred and sixty patent family members on SAREPTA THERAPS INC drugs in twenty-three countries.
Summary for Sarepta Theraps Inc
| International Patents: | 160 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Sarepta Theraps Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | 9,018,368 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | 8,486,907 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-001 | Sep 19, 2016 | RX | Yes | Yes | 9,416,361 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Sarepta Theraps Inc | EXONDYS 51 | eteplirsen | SOLUTION;INTRAVENOUS | 206488-002 | Sep 19, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Sarepta Theraps Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,035,040 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | ➤ Try a Free Trial |
| 9,441,229 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | ➤ Try a Free Trial |
| 8,476,423 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | ➤ Try a Free Trial |
| 8,785,407 | Antisense antiviral agent and method for treating ssRNA viral infection | ➤ Try a Free Trial |
| 8,524,880 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | ➤ Try a Free Trial |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Sarepta Theraps Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| China | 105307723 | ➤ Try a Free Trial |
| Japan | 2003533986 | ➤ Try a Free Trial |
| Japan | 2008513012 | ➤ Try a Free Trial |
| Canada | 2550642 | ➤ Try a Free Trial |
| Japan | 2010505741 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.
